1. Scrip
  2. >>Business

Zydus Partners Medicure To Launch First Branded Drug In US

 
• By Penelope MacRae

Zydus Cadila is teaming up with Canada’s Medicure Inc to launch cholesterol control medication Zypitamag, its first branded drug in the key US market, as the Indian firm drives ahead with a strategy of diversifying from low-priced generics.

Pharma pills
ZYDUS AND MEDICURE HAVE JOINED HANDS IN THE US

Zydus Cadila announced it has struck a deal with a subsidiary of cardiovascular drug discovery firm Medicure Inc. to market cholesterol management drug Zypitamag in the US. The debut of Zypitamag (pitavastatin magnesium) “marks the first branded product launch for Zydus in the US,” the Indian company said in a statement.

The proprietary drug’s launch is part of Zydus Cadila’s quest to explore “new pathways in pharmaceutical technology,” said company managing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

GSK Gains Hengrui’s PDE3/4 inhibitor, Options For 11 Early Assets In Potential $12bn Deal

 
• By Dexter Jie Yan

Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Sanofi’s Vicebio buy; Sarepta halts US Elevidys shipments; Novartis warning over Europe; US CRL for Genentech’s Columvi; and an interview with Novavax.

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 
• By Jessica Merrill

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

More from Scrip

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 
• By Jessica Merrill

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

GSK’s Blenrep US Setback Could Go From Bad To Worse

 
• By Sushmita Panda

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.